Nature of the Business	6 Months Ended
Jun. 30, 2025
Accounting Policies [Abstract]
Nature of the Business	1. Nature of the Business Vor Biopharma Inc. (the “Company”) is a clinical-stage company advancing telitacicept, a novel, dual-target recombinant fusion protein that inhibits both BLyS (BAFF) and APRIL—two key cytokines involved in B cell survival and autoantibody production. This dual-target mechanism reduces autoreactive B cells and autoantibody production, key drivers of autoimmune pathology. The Company is headquartered in Massachusetts. The Company was incorporated on December 30, 2015. Risks and Uncertainties The Company is subject to a number of risks common to development stage companies in the biotechnology industry, including, but not limited to, risks of failure of clinical trials, dependence on key personnel, protection of proprietary technology, reliance on third party organizations, uncertainty of obtaining regulatory approval for any product candidate that it may develop, development by competitors of technological innovations, compliance with government regulations, adverse macroeconomic conditions and the need to obtain additional financing. The Company anticipates that it will continue to incur significant operating losses for the next several years as it continues to develop its product candidate and any future product candidates. As a result, the Company’s continued operations are dependent on its ability to raise additional funding. If the Company is unable to obtain additional funding on a timely basis, it may be forced to significantly curtail, delay, or discontinue one or more of its clinical trials or be unable to expand its operations. Liquidity and Capital Resources As of June 30, 2025, the Company had $200.6 million of cash, cash equivalents and marketable securities and an accumulated deficit of $2,063.1 million. The Company anticipates that it will continue to incur significant operating losses for the next several years as it continues to develop, and if approved commercialize, its product candidate and any future product candidates. As a result, the Company’s continued operations are dependent on its ability to raise additional funding. In June 2025, the Company raised $174.4 million in net cash proceeds through the issuance of the 2025 PIPE Warrants (as defined below). Refer to Note 7 for additional information on the 2025 PIPE Warrants. The Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the condensed consolidated financial statements are issued. As a result of the issuance of the 2025 Warrants and receipt of the associated net cash proceeds, the Company has alleviated the substantial doubt that previously existed and management believes, based on its current operating plans, the Company has sufficient liquidity to satisfy its obligations over the next twelve months from the date of issuance of these condensed consolidated financial statements.

Nature of the Business

6 Months Ended

Jun. 30, 2025

1. Nature of the Business

Vor Biopharma Inc. (the “Company”) is a clinical-stage company advancing telitacicept, a novel, dual-target recombinant fusion protein that inhibits both BLyS (BAFF) and APRIL—two key cytokines involved in B cell survival and autoantibody production. This dual-target mechanism reduces autoreactive B cells and autoantibody production, key drivers of autoimmune pathology. The Company is headquartered in Massachusetts. The Company was incorporated on December 30, 2015.

Risks and Uncertainties

The Company is subject to a number of risks common to development stage companies in the biotechnology industry, including, but not limited to, risks of failure of clinical trials, dependence on key personnel, protection of proprietary technology, reliance on third party organizations, uncertainty of obtaining regulatory approval for any product candidate that it may develop, development by competitors of technological innovations, compliance with government regulations, adverse macroeconomic conditions and the need to obtain additional financing.

The Company anticipates that it will continue to incur significant operating losses for the next several years as it continues to develop its product candidate and any future product candidates. As a result, the Company’s continued operations are dependent on its ability to raise additional funding. If the Company is unable to obtain additional funding on a timely basis, it may be forced to significantly curtail, delay, or discontinue one or more of its clinical trials or be unable to expand its operations.

Liquidity and Capital Resources

As of June 30, 2025, the Company had $200.6 million of cash, cash equivalents and marketable securities and an accumulated deficit of $2,063.1 million. The Company anticipates that it will continue to incur significant operating losses for the next several years as it continues to develop, and if approved commercialize, its product candidate and any future product candidates. As a result, the Company’s continued operations are dependent on its ability to raise additional funding. In June 2025, the Company raised $174.4 million in net cash proceeds through the issuance of the 2025 PIPE Warrants (as defined below). Refer to Note 7 for additional information on the 2025 PIPE Warrants.

The Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the condensed consolidated financial statements are issued. As a result of the issuance of the 2025 Warrants and receipt of the associated net cash proceeds, the Company has alleviated the substantial doubt that previously existed and management believes, based on its current operating plans, the Company has sufficient liquidity to satisfy its obligations over the next twelve months from the date of issuance of these condensed consolidated financial statements.